European Journal of Clinical Pharmacology

, Volume 64, Issue 6, pp 555–563

Anticoagulant effects of Idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials

Authors

    • 4th Department of MedicineUniversity Hospital Mannheim
  • Ingrid Jörg
    • 4th Department of MedicineUniversity Hospital Mannheim
  • Yvonne Vukojevic
    • 4th Department of MedicineUniversity Hospital Mannheim
  • Gerd Mikus
    • Department of Clinical Pharmacology and PharmacoepidemiologyUniversity of Heidelberg
  • Christel Weiss
    • Institute for Biometrics and StatisticsUniversity Hospital Mannheim
Review Article

DOI: 10.1007/s00228-008-0463-0

Cite this article as:
Harenberg, J., Jörg, I., Vukojevic, Y. et al. Eur J Clin Pharmacol (2008) 64: 555. doi:10.1007/s00228-008-0463-0

Abstract

Aim

To gather information on anticoagulant effects after the termination of long-term therapy with idraparinux.

Methods

The anticoagulant effects of idraparinux, a synthetic polymethylated analogue of its pentasaccharide, were analysed in 23 patients after termination of a 6- or 12-month therapy period for the prevention of recurrent venous thromboembolism (VTE). Plasma samples of patients initially randomized to 2.5 mg idraparinux (normal creatinine clearance) or 1.5 mg idraparinux (creatinine clearance <30 ml/min) were investigated in the van Gogh trials. At 3-month intervals for up to 15 months following the termination of the therapy, the factor Xa-specific S2222 chromogenic substrate (aXa) assay and Heptest were used to determine various pharmacokinetic parameters and prothrombin-induced clotting time (PiCT), activated partial thromboplastin time (aPTT) and prothrombin time (PT) were determined.

Results

Based on the aXa assay and Heptest, the half lives (t1/2) were 60.2 days and 107.7 days (p < 0.0001), maximum drug concentrations (Cmax) were 0.30 and 0.39 μg/l (p = 0.0016), areas under the activity time curve (AUC) were 33.7 and 38.0 μg/l per day (p = 0.0002), plasma clearances were 0.09 and 0.06 ml/min (p < 0.0001), mean residence times (MRT) were 75.4 and 121.9 (p < 0.0001) and volumes of distribution (Vdiss) were 7.4 and 8.6 l (p = 0.1336), respectively. After 12 months of treatment (n = 18), the S2222 and Heptest results showed significantly higher Cmax and AUC, lower Vdiss and clearance and unchanged t1/2 and MRT values compared to 6 months of treatment (n = 5). The PiCT was prolonged for a period of 9 months. Coagulation times of aPTT and PT were not influenced. The results of these parameters did not differ between 12 and 6 months of treatment.

Conclusion

The data support reports on a non-ionic binding of idraparinux to antithrombin and other proteins. We suggest that these findings may explain some of the findings of the van Gogh Extension trial.

Keywords

Anticoagulants Anticoagulation Idraparinux Pharmacodynamics Thrombosis Venous thromboembolism

Copyright information

© Springer-Verlag 2008